Related Experiment Videos
CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases
M Paganuzzi1, M Onetto, P Marroni
1Division of Clinical Pathology, National Institute for Cancer Research, Genova, Italy.
Insights
Serum CA 19-9 and CA 50 antigen levels are useful for detecting pancreatic cancer in nonjaundiced patients. While both markers show high correlation, their combined use offers no diagnostic advantage over individual assessment.
Area of Science:
- Oncology
- Gastroenterology
- Biochemistry
Background:
- Pancreatic cancer diagnosis often relies on tumor markers.
- CA 19-9 and CA 50 are established tumor markers for gastrointestinal malignancies.
- Understanding their comparative utility in biliary and pancreatic diseases is crucial.
Purpose of the Study:
- To evaluate and compare the diagnostic performance of serum CA 19-9 and CA 50.
- To assess these markers in patients with malignant and benign biliary and pancreatic diseases.
- To determine if combined use of CA 19-9 and CA 50 improves diagnostic accuracy.
Main Methods:
- Serum concentrations of CA 19-9 and CA 50 were measured.
- 129 patients with diagnosed biliary and pancreatic diseases (malignant and benign) were included.
- Statistical analysis was performed to compare marker values, sensitivity, specificity, and correlation.
Main Results:
- CA 19-9 and CA 50 levels were highly correlated (P < 0.001).
- Pancreatic cancer detection rates were 84.6% for CA 19-9 and 80.7% for CA 50.
- CA 19-9 showed higher specificity (92.4%) than CA 50 (88.5%). CA 50 had higher sensitivity (91.3%) for biliary tract diseases compared to CA 19-9 (73.9%).
- Elevated levels were observed in benign conditions, particularly obstructive jaundice.
- Combined use of CA 19-9 and CA 50 did not enhance diagnostic resolution.
Conclusions:
- Both CA 19-9 and CA 50 are valuable markers for pancreatic cancer, especially in nonjaundiced patients.
- CA 19-9 offers slightly better specificity, while CA 50 demonstrates higher sensitivity for biliary tract diseases.
- The combined application of CA 19-9 and CA 50 does not provide superior diagnostic accuracy compared to using either marker alone.
Abstract:
Serum concentrations of the CA 19-9 and CA 50 antigens were determined in 129 patients with malignant and benign biliary and pancreatic diseases. Values for the two markers were highly correlated (P less than 0.001). The concentrations of CA 19-9 and CA 50 were positive in 84.6% and 80.7% of patients with pancreatic cancer, respectively. The overall specificity of CA 19-9 (92.4%) was slightly higher than that of CA 50 (88.5%). The sensitivity of CA 50 (91.3%) was greater than that of CA 19-9 (73.9%) in patients with diseases of the biliary tract. Elevated concentrations of CA 19-9 (12.9%) and CA 50 (35.2%) were also found in a number of cases with benign disease, especially in patients with obstructive jaundice. These data suggest that both CA 19-9 and CA 50 can be useful markers of pancreatic cancer in nonjaundiced patients. The joint use of the two markers does not yield a better diagnostic resolution than the use of either one alone.